Motilal Oswal: Healthcare Sector Outlook - Slow Healing To Normalcy In India, Emerging Markets; Cost Remains Controlled
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
We concluded our 16th Annual General Investor Conference, which saw participation from 14 domestic pharma companies across various product segments.
Outlook for domestic formulations improving gradually: With the easing of lockdown measures, connect between medical representative and doctor is reviving at a rapid pace. 80–90% of MRs are now on the field, and face-to-face meetings have also commenced.
At the same time, structural transformation is underway with the increased use of digital tools, which would aid sustained cost savings, to some extent.
Demand for chronic therapies has been steady, while demand for acute therapies is picking up at a gradual pace.
Emerging Markets continue to reel under the impact of Covid-19 and currency depreciation.
MR activity is picking up as the worst phase of Covid-19 is expected to be over in Brazil and Russia.
Unfavorable currency remains a challenge, and companies are hedging against the vagaries of currency volatility.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.